Mirikizumab is a recently FDA-approved drug for treating ulcerative colitis (UC). It's shown efficacy not only in UC but also in Crohn's disease, another inflammatory bowel disease. Other newer treatments for UC include etrasimod and risankizumab (Skyrizi), also approved by the FDA for moderate to severe UC. Guselkumab (Tremfya), while not specifically developed for UC, shows promise in treating the condition by targeting a key inflammatory cytokine. These are just some of the newer medications being used or studied to treat ulcerative colitis.
Key New UC Drugs:
- Mirikizumab: Approved for ulcerative colitis and showing promise for Crohn's disease. Studies show long-term efficacy and safety. [Source: Multiple News Articles]
- Etrasimod: Recommended by NICE (National Institute for Health and Care Excellence) for patients who haven't responded well to other treatments. [Source: Pharmaceutical Journal Article]
- Risankizumab (Skyrizi): FDA approved for moderate to severe ulcerative colitis. [Source: Abbvie Press Release]
- Guselkumab (Tremfya): While primarily for other autoimmune diseases, studies indicate its effectiveness in treating UC. [Source: University of Chicago Medicine Article]
This information should not be considered medical advice. Consult a healthcare professional for any health concerns.
